News for Healthier Living

ASH 2025: New Combination Approach Aims to Make CAR T More Durable in Lymphoma

EMBARGOED: A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma. Findings to be presented at ASH Dec. 8, 2025.

December 8, 2025


December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

November 26 2025

November 25 2025